The 0.01% Simple Moving Average of Ngm Biopharmaceuticals Inc’s (NGM) Stock in the Past 200 Days

The stock of Ngm Biopharmaceuticals Inc (NGM) has seen a 0.74% increase in the past week, with a 2.72% gain in the past month, and a 24.91% flourish in the past quarter. The volatility ratio for the week is 2.79%, and the volatility levels for the past 30 days are at 2.19% for NGM. The simple moving average for the last 20 days is 0.64% for NGM’s stock, with a simple moving average of 0.01% for the last 200 days.

Is It Worth Investing in Ngm Biopharmaceuticals Inc (NASDAQ: NGM) Right Now?

Company’s 36-month beta value is 1.26.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for NGM is 52.55M, and currently, short sellers hold a 3.19% ratio of that floaft. The average trading volume of NGM on April 03, 2024 was 1.11M shares.

NGM) stock’s latest price update

Ngm Biopharmaceuticals Inc (NASDAQ: NGM)’s stock price has gone rise by 0.09 in comparison to its previous close of 1.56, however, the company has experienced a 0.74% increase in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-19 that SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

NGM Trading at 1.83% from the 50-Day Moving Average

After a stumble in the market that brought NGM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.71% of loss for the given period.

Volatility was left at 2.19%, however, over the last 30 days, the volatility rate increased by 2.79%, as shares surge +2.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.27% upper at present.

During the last 5 trading sessions, NGM rose by +0.97%, which changed the moving average for the period of 200-days by -55.79% in comparison to the 20-day moving average, which settled at $1.5532. In addition, Ngm Biopharmaceuticals Inc saw 81.77% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NGM starting from COLUMN GROUP L P, who purchase 5,840 shares at the price of $0.62 back on Nov 16 ’23. After this action, COLUMN GROUP L P now owns 949,862 shares of Ngm Biopharmaceuticals Inc, valued at $3,627 using the latest closing price.

COLUMN GROUP L P, the Director of Ngm Biopharmaceuticals Inc, purchase 5,840 shares at $0.62 during a trade that took place back on Nov 16 ’23, which means that COLUMN GROUP L P is holding 949,862 shares at $3,627 based on the most recent closing price.

Stock Fundamentals for NGM

Current profitability levels for the company are sitting at:

  • -34.29 for the present operating margin
  • 0.26 for the gross margin

The net margin for Ngm Biopharmaceuticals Inc stands at -31.66. The total capital return value is set at -1.02. Equity return is now at value -69.76, with -59.79 for asset returns.

Currently, EBITDA for the company is -144.33 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 16.35. The receivables turnover for the company is 76.16for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.79.

Conclusion

In a nutshell, Ngm Biopharmaceuticals Inc (NGM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts